CN

Pipeline

Overview

Medilink has developed ADC-related technologies with independent intellectual property rights, where the indications have covered the top 10 tumor fields in terms of morbidity and mortality.

The following table summarizes the development status of our drug candidates and each drug candidate as of the latest practicable date:

Project

Target

Indications

Platform

Discovery

Pre -Clinical

IND

Phase 1

Phase 2

Phase 3

BLA

YL201

-

Solid Tumor

TMALIN

 

 

 

 

 

 

 

YL202

-

Solid Tumor

TMALIN

 

 

 

 

 

 

 

Project 3

-

Solid Tumor

TMALIN

 

 

 

 

 

 

 

Project 4

-

Solid Tumor

TMALIN

 

 

 

 

 

 

 

Project 5

-

Solid Tumor

TMALIN

 

 

 

 

 

 

 

Project 6

-

Solid Tumor

TMALIN

 

 

 

 

 

 

 

Project 7

-

Solid Tumor

TMALIN